AFWM
ALLO icon

Abich Financial Wealth Management’s Allogene Therapeutics ALLO Stock Holding History

Abich Financial Wealth Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-283
Closed -$659 – 397
2024
Q2 		$659 Buy
+283
New +$835 ﹤0.01% 686

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Abich Financial Wealth Management's ALLO Position: Q3 2024 in Review

Abich Financial Wealth Management sold out of Allogene Therapeutics (ALLO) in Q3 2024, closing a stake of 283 shares — an estimated $659 sold.

Abich Financial Wealth Management first reported a position in ALLO in Q2 2024 and held it in 1 quarter. The position peaked at $659 in Q2 2024. 156 funds tracked by Wall St. Rank hold ALLO as of Q3 2024.

  • Abich Financial Wealth Management reported no remaining Allogene Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Abich Financial Wealth Management sold 283 Allogene Therapeutics shares in Q3 2024, an estimated $659.
  • Abich Financial Wealth Management first reported a position in Allogene Therapeutics in Q2 2024 and held it in 1 quarter.
  • Abich Financial Wealth Management's Allogene Therapeutics position peaked at $659 in Q2 2024.
  • 156 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2024.

Based on Abich Financial Wealth Management's 13F filing for Q3 2024, filed 25 Oct 2024.